Is IDYA a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Darovasertib approval and launch in uveal melanoma, with revenue (ttm) at ~$234M, almost all a Q3 2025 partnership payment (~$208M); Q2 2026 collaboration revenue ~$8.9M. The bear case rests on as a clinical-stage biotech, IDEAYA has minimal product revenue and posts ongoing operating losses, so the equity is valued on pipeline expectations that can swing sharply on trial and regulatory news. Analysts covering it are spread from $31.00 to $65.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. As a clinical-stage biotech, IDEAYA has minimal product revenue and posts ongoing operating losses, so the equity is valued on pipeline expectations that can swing sharply on trial and regulatory news. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $31.00, -5.6% from the $32.85 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Darovasertib approval and launch in uveal melanoma. The positive OptimUM-02 readout (HR 0.42) supports an NDA filing in H2 2026 for first-line HLA-A*02:01-negative metastatic uveal melanoma, reviewed under the FDA's Real-Time Oncology Review pathway. The most optimistic analyst target on IDYA is $65.00, +97.9% from the $32.85 price. That figure is only reachable if this thesis works close to its best case.

As a clinical-stage biotech, IDEAYA has minimal product revenue and posts ongoing operating losses, so the equity is valued on pipeline expectations that can swing sharply on trial and regulatory news. The FDA could delay or decline the darovasertib NDA, or approval could come with a narrow label or slow commercial uptake in a rare indication. Earlier-stage programs (IDE397, IDE849, IDE161 and others) carry high failure rates typical of oncology drug development. Despite a large cash balance, continued spending and a recent shelf registration point to future dilution as a likely funding mechanism. The company also faces competition from established and emerging therapies in its target indications, and the stock is historically volatile around data catalysts, as the ~14% slide in the month to mid October 2026 showed. Running two Phase 3 programs at once (OptimUM-11 and the planned IDE849 trial) raises the spending rate, and Q2 2026 EPS of -$1.22 missed the ~-$1.05 consensus. The most pessimistic published target is $31.00, -5.6% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Darovasertib approval and launch in uveal melanoma) stalling in the reported numbers rather than in the narrative, the risk above (as a clinical-stage biotech, IDEAYA has minimal product revenue and posts ongoing operating losses, so the equity is valued on pipeline expectations that can swing sharply on trial and regulatory news) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

IDEAYA is a clinical-stage precision-oncology company that develops targeted cancer therapies using a synthetic-lethality approach, which exploits genetic weaknesses specific to tumor cells. Its lead drug, darovasertib, targets uveal melanoma, and it has a broader pipeline of biomarker-defined small molecules and an antibody-drug conjugate.

IDEAYA has no approved product yet, so it earns only modest collaboration revenue rather than product sales. Being pre-revenue is normal for a clinical-stage biotech, whose value comes from the potential of its drug candidates rather than current earnings, and which funds operations from cash raised in the markets.

Darovasertib (IDE196) is IDEAYA's lead candidate, a protein kinase C inhibitor for uveal melanoma, a rare eye cancer. In 2026 its registrational OptimUM-02 trial met its primary endpoint, supporting a planned H2 2026 FDA filing, so darovasertib is the single largest driver of the company's near-term value.